



ASX ANNOUNCEMENT

18 September 2020

CardieX Granted New Blood Pressure Patent

Highlights:

- Patent EP2566387 has been granted by the European Patent Office to protect the Company's intellectual property surrounding its SphygmoCor® technology used in cuff-based brachial blood pressure (BP) devices.
- Examining officers specifically referenced the unique nature of the new patent being granted, demonstrating the Company's unique and proprietary intellectual property for measuring cardiovascular health with a brachial cuff.
- New patent in force until March 2034.

CardieX Limited (ASX: CDX) (CardieX, the Company) is pleased to announce that CardieX subsidiary ATCOR has been granted a new patent by the European Patent Office (EPO) in relation to the intellectual property (IP) for the Company's proprietary SphygmoCor® technology used in cuff-based blood pressure devices.

EPO Patent Number **EP2566387** further protects the Company's IP in relation to the measurement of a whole central blood pressure waveform with cardiovascular features using a brachial cuff. Patent **EP2566387** specifically covers non-invasively estimating the heart's pressure and pressure waveform with features related to cardiac function and arterial properties using a conventional BP cuff inflated to low pressure. The patent provides a non-invasive, simple, and operator-independent tool to clinically diagnose the cardiovascular system and estimate the risk of having heart disease which otherwise would require an invasive procedure.

Examining officers from the EPO specifically referenced the substantial differences in respect of any other existing patents when granting the new patent to ATCOR, demonstrating the unique nature of the technology.

The granting of the European patent follows similar patents already granted to the Company in the United States (refer ASX release 9 March 2016) and Japan (refer ASX release 3 March 2016), with the new European patent in force until 2034.

ATCOR's SphygmoCor® technology is the global standard for the non-invasive measurement of arterial stiffness in medical settings with all "Top 20 USA Hospitals" using ATCOR's



SphygmoCor® technology, over 4500 installations worldwide, and used by major pharmaceutical companies and research institutions such as The Mayo Clinic, GlaxoSmithKline, AstraZeneca, Bayer, Scripps, Johns Hopkins, and Stanford University.

ATCOR currently sells the XCEL central blood pressure device and has a partnership with SunTech Medical in relation to the Oscar 2 ABPM device - both of which incorporate ATCOR's SphygmoCor® technology and brachial cuff IP. The Company also recently announced a new partnership with Andon for the development of a home-based BP monitoring device with advanced cardiovascular vital signs features (refer ASX release 7 September 2020).

Craig Cooper, CEO & Managing Director of CardieX commented:

"We are very pleased to be granted this new patent to protect our IP in Europe. Of great significance is the findings of the examining officers from the EPO which were similar to the findings we received from examiners in the US in 2016 - that there are substantial differences in respect of any other existing patents – further demonstrating and validating the uniqueness of our technology".

Authorised for release by the full Board of Directors, and released by Jarrod White

For more information please contact:

Investor Relations

Rod Hinchcliffe

rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton

melissa.hamilton@mcpartners.com

About CardieX

CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders. The company's ATCOR division is the world leader in medical devices for measuring arterial stiffness and central blood pressure waveforms based on its unique FDA-cleared and patented SphygmoCor® technology. Under the ATCOR.X brand, the company also develops and licenses its Arty™ platform consisting of physiological and health analytics for wearable devices. The company's digital platform, ArtyNet™, is a connected SaaS ecosystem providing physicians with a complete telehealth solution for remotely managing patients' health (2021 launch).